Clinical

Dataset Information

0

Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers


ABSTRACT: This is a randomized, placebo-controlled Phase I/II multi-center trial, of the safety and efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers. The three proposed intervention arms are: Celecoxib (to be provided by Searle) will be administered at 200mg p.o. BID x 12 months or 400mg p.o. BID x 12 months vs. Placebo p.o. BID x 12 months. Assessment of endoscopic and tissue-based biomarker endpoints will be conducted at baseline and 12 months on study drug or placebo. Patients that present with polyps at baseline will undergo a month 4 endoscopy. Plasma drug trough samples for pharmacokinetic analyses will be collected at baseline and month 12. NCI-Chemoprevention Branch will coordinate the efforts and activities of all sites. Safety monitoring will occur via in-patient interviews with exams at month twelve; symptom questionnaires completed at baseline, months one, four, eight and twelve; blood and urinalysis at baseline and at months one, four, eight and twelve. A post-administration telephone call to evaluate side effect resolution will occur at months 13-14 for patients who have unresolved adverse events at the end of month 12.

DISEASE(S): Hereditary Nonpolyposis,Colorectal Neoplasm,Colorectal Neoplasms,Colorectal Neoplasms, Hereditary Nonpolyposis

PROVIDER: 2001464 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-02-01 | GSE217067 | GEO
2019-08-21 | GSE135455 | GEO
2015-11-03 | E-GEOD-64930 | biostudies-arrayexpress
2009-12-31 | GSE17590 | GEO
| phs000605 | dbGaP
2024-09-02 | BIOMD0000000673 | BioModels
2015-11-22 | GSE57110 | GEO
2020-09-01 | GSE157177 | GEO
2011-06-01 | E-GEOD-27140 | biostudies-arrayexpress
2016-06-30 | E-GEOD-69967 | biostudies-arrayexpress